Cynthia M. Chavez-Eng
Research Subjects
Cynthia M. Chavez-Eng has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Kevin P. Bateman
Merck, West Point, PA, USA
2 shared publications A Jones
1 shared publication- B. K. Matuszewski
Merck Research Laboratories, West Point, Pennsylvania 19486, USA
1 shared publication B.K. Matuszewski
Merck & Co. Inc., WP42-208, Merck Research Laboratories, P.O. Box 4, West Point, PA 19486, USA
1 shared publicationD Dean
1 shared publicationD Melillo
1 shared publication
Latest Publications
- 1 July 2018
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 107 (7) , 1973-1986
Microdosing Cocktail Assay Development for Drug–Drug Interaction Studies
- 1 July 2018
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 107 (7) , 1973-1986
Microdosing Cocktail Assay Development for Drug–Drug Interaction Studies
- 1 February 2016
- Published by Elsevier in Journal of Chromatography B
- Vol. 1011, 204-214
Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry
- 1 February 2016
- Published by Elsevier in Journal of Chromatography B
- Vol. 1011, 204-214
Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry
- 3 September 2004
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 35 (5) , 1213-1229
Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection
- 3 September 2004
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 35 (5) , 1213-1229
Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection
- 16 February 2003
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 73 (2) , P66
Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects
- 16 February 2003
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 73 (2) , P66
Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects
- 1 December 2001
- Vol. 29 (12) , 1614-28
Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.
Rofecoxib is a potent and highly selective cyclooxygenase-2 inhibitor used for the treatment of osteoarthritis and pain. Following administration of [4-(14)C]rofecoxib to intact rats, the plasma C(max) (at approximately 1 h) was followed by a secondary C(max) (at approximately 10 h), which was not observed in bile duct-cannulated rats. Following administration of [4-(14)C]5-hydroxyrofecoxib to intact or bile duct-cannulated rats, radiolabeled rofecoxib was detected in plasma, and once again a secondary C(max) for rofecoxib was observed (at approximately 10 h), which occurred only in the intact animals. These results indicate that reversible metabolism of rofecoxib to 5-hydroxyrofecoxib occurs in the rat and that the process is dependent upon an uninterrupted bile flow. Studies on the contents of the gastrointestinal tract of rats showed that conversion of 5-hydroxyrofecoxib to parent compound occurs largely in the lower intestine. Treatment of rats with [5-(18)O]5-hydroxyrofecoxib, followed by liquid chromatography-tandem mass spectrometry analyses of plasma samples, confirmed that 5-hydroxyrofecoxib undergoes metabolism to the parent drug, yielding [1-(18)O]rofecoxib, [2-(18)O]rofecoxib, and unlabeled rofecoxib. Similarly, treatment with [1,2-(18)O(2)]rofecoxib afforded the same three isotopic variants of rofecoxib. These findings are consistent with a metabolic sequence involving 5-hydroxylation of rofecoxib, biliary elimination of the corresponding glucuronide, and deconjugation of the glucuronide in the lower gastrointestinal tract. Reduction of the 5-hydroxyrofecoxib thus liberated yields a hydroxyacid that cyclizes spontaneously to regenerate rofecoxib, which is reabsorbed and enters the systemic circulation. This sequence represents a novel form of enterohepatic recycling and reflects the susceptibility of 5-hydroxyrofecoxib, as well as rofecoxib itself, to reversible 2-furanone ring opening under in vivo conditions.
- 1 December 2001
- Vol. 29 (12) , 1614-28
Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques.
Rofecoxib is a potent and highly selective cyclooxygenase-2 inhibitor used for the treatment of osteoarthritis and pain. Following administration of [4-(14)C]rofecoxib to intact rats, the plasma C(max) (at approximately 1 h) was followed by a secondary C(max) (at approximately 10 h), which was not observed in bile duct-cannulated rats. Following administration of [4-(14)C]5-hydroxyrofecoxib to intact or bile duct-cannulated rats, radiolabeled rofecoxib was detected in plasma, and once again a secondary C(max) for rofecoxib was observed (at approximately 10 h), which occurred only in the intact animals. These results indicate that reversible metabolism of rofecoxib to 5-hydroxyrofecoxib occurs in the rat and that the process is dependent upon an uninterrupted bile flow. Studies on the contents of the gastrointestinal tract of rats showed that conversion of 5-hydroxyrofecoxib to parent compound occurs largely in the lower intestine. Treatment of rats with [5-(18)O]5-hydroxyrofecoxib, followed by liquid chromatography-tandem mass spectrometry analyses of plasma samples, confirmed that 5-hydroxyrofecoxib undergoes metabolism to the parent drug, yielding [1-(18)O]rofecoxib, [2-(18)O]rofecoxib, and unlabeled rofecoxib. Similarly, treatment with [1,2-(18)O(2)]rofecoxib afforded the same three isotopic variants of rofecoxib. These findings are consistent with a metabolic sequence involving 5-hydroxylation of rofecoxib, biliary elimination of the corresponding glucuronide, and deconjugation of the glucuronide in the lower gastrointestinal tract. Reduction of the 5-hydroxyrofecoxib thus liberated yields a hydroxyacid that cyclizes spontaneously to regenerate rofecoxib, which is reabsorbed and enters the systemic circulation. This sequence represents a novel form of enterohepatic recycling and reflects the susceptibility of 5-hydroxyrofecoxib, as well as rofecoxib itself, to reversible 2-furanone ring opening under in vivo conditions.